HomeREGULATORY
REGULATORY

MHLW Advisory Panel Gives Nod to Eli Lilly’s JAK Inhibitor Baricitinib
(May.31.2017)

A key advisory committee of the Ministry of Health, Labor and Welfare (MHLW) on May 30 recommended approval for Eli Lilly Japan’s rheumatoid arthritis (RA) drug baricitinib, which was approved in Europe earlier this year but rejected in the US last month ...
(LOG IN FOR FULL STORY)

News Calendar